Is personalization of care coming to pancreatic oncology?

Annals of Surgical Oncology

Volumn 20, Issue 2, 2013, Pages 355-356

  Crane, Christopher H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; SMAD4 PROTEIN;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; EDITORIAL; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATICODUODENECTOMY; PERSONALIZED MEDICINE; PROTEIN EXPRESSION;

HUMANS; INDIVIDUALIZED MEDICINE; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878540095     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2770-z     Document Type: Editorial

References (4)

1. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136:187-95.
2. Bhutani MS. The year of improved tissue acquisition, randomized trials, and endoscopic ultrasound-guided therapy. Endoscopy 2011;43:993-999.
3. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806-13.
4. Crane CH, Varadhachary GR, Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011;29:3037-43.